{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:35:17Z","timestamp":1787499317194,"version":"build-2736575974"},"reference-count":53,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Previously, we reported that targeting immunoglobulin superfamily member 9 (IGSF9) could enhance antitumor T-cell activity and sensitivity to anti\u2013PD-1 immunotherapy, although the detailed mechanism remains unclear. In this study, we find that, similar to the regulation of PD-L1 expression, interferon gamma (IFN-\u03b3) also induces the expression of IGSF9 in acute myeloid leukemia (AML). The small interfering RNA specifically targeting JAK1 and a STAT1 inhibitor blocking IFN-\u03b3 signal pathway significantly inhibit the expression of IGSF9 and PD-L1. As a tumor-specific immune checkpoint molecule, IGSF9 plays a significant role in promoting tumor escape. The induction of both PD-L1 and IGSF9 by IFN-\u03b3 in the tumor microenvironment explains why IGSF9 is highly expressed in tumors and tumor-infiltrating immune cells. This induction also underpins the strong synergistic effects when combining anti-IGSF9 and anti\u2013PD-1 therapies. Additionally, IGSF9 also mediates the extramedullary infiltration of AML cells, which can be inhibited by depletion of IGSF9 or anti-IGSF9. The binding epitopes of anti-IGSF9 are located within the immunoglobulin G2 and fibronectin type-III-2 domains of IGSF9. Based on these findings, we develop an antibody-drug conjugate (ADC) targeting IGSF9 (anti\u2013IGSF9-linker-DXd). This ADC exhibits 99.7% purity, and primarily exists in monomeric form, demonstrating excellent homogeneity (drug-to-antibody ratio, 8-10) and specificity. Anti\u2013IGSF9-linker-DXd effectively kills IGSF9-positive tumor cells and exhibits a potent bystander effect. In vivo, anti\u2013IGSF9-linker-DXd almost completely eliminates early- and mid-stage tumors and significantly inhibits the progression of advanced tumors. In summary, our findings underscore the potential of IGSF9 as a novel therapeutic target for AML treatment, highlighting its role in disease progression and the efficacy of targeted therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016432","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T15:11:07Z","timestamp":1750173067000},"page":"4217-4231","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["IGSF9-targeted therapy inhibits the progression of acute myeloid leukemia"],"prefix":"10.1182","volume":"9","author":[{"given":"Lijun","family":"Hui","sequence":"first","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Binzhou Medical University, Yantai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xiao","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Yantaishan Hospital, Yantai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiling","family":"Zhao","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Binzhou Medical University, Yantai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Binzhou Medical University, Yantai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Luan","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Binzhou Medical University, Yantai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiashen","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Binzhou Medical University, Yantai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiao","family":"Sun","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Binzhou Medical University, Yantai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhui","family":"Meng","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Binzhou Medical University, Yantai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Binzhou Medical University, Yantai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Binzhou Medical University, Yantai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangmin","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Binzhou Medical University, Yantai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhao","family":"Ji","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Binzhou Medical University, Yantai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Wei","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Binzhou Medical University, Yantai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Binzhou Medical University, Yantai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yu","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Binzhou Medical University, Yantai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyun","family":"Zheng","sequence":"additional","affiliation":[{"name":"3Department of Hematology, The Second Hospital of Shandong University, Jinan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Jiang","sequence":"additional","affiliation":[{"name":"3Department of Hematology, The Second Hospital of Shandong University, Jinan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaopeng","family":"Wang","sequence":"additional","affiliation":[{"name":"4Department of Thoracic Surgery, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0502-563X","authenticated-orcid":false,"given":"Zunling","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Binzhou Medical University, Yantai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"issue":"1","key":"2025082608265606600_bib1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-022-01267-7","article-title":"Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations","volume":"15","author":"Eckardt","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"13","key":"2025082608265606600_bib2","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood"},{"issue":"7","key":"2025082608265606600_bib3","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood.2022017046","article-title":"C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse","volume":"141","author":"Yang","year":"2023","journal-title":"Blood"},{"issue":"29","key":"2025082608265606600_bib4","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1200\/JCO.2016.67.5892","article-title":"Extramedullary disease in adult acute myeloid leukemia is common but lacks independent significance: analysis of patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008 [published correction appears in J Clin Oncol. 2017;35(2):263]","volume":"34","author":"Ganzel","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025082608265606600_bib5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13045-016-0337-3","article-title":"DNMT3A mutation leads to leukemic extramedullary infiltration mediated by TWIST1","volume":"9","author":"Xu","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2025082608265606600_bib6","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1200\/JCO.2000.18.6.1295","article-title":"CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy","volume":"18","author":"Ferrara","year":"2000","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025082608265606600_bib7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.1999.17.1.293","article-title":"CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?","volume":"17","author":"Murray","year":"1999","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025082608265606600_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.20739","article-title":"Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Yang","year":"2007","journal-title":"Am J Hematol"},{"issue":"23","key":"2025082608265606600_bib9","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"2025082608265606600_bib10","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","article-title":"Current status and future perspectives in targeted therapy of NPM1-mutated AML","volume":"36","author":"Ranieri","year":"2022","journal-title":"Leukemia"},{"issue":"14","key":"2025082608265606600_bib11","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1182\/blood-2011-04-347229","article-title":"How I treat extramedullary acute myeloid leukemia","volume":"118","author":"Bakst","year":"2011","journal-title":"Blood"},{"issue":"7728","key":"2025082608265606600_bib12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","article-title":"LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration","volume":"562","author":"Deng","year":"2018","journal-title":"Nature"},{"issue":"3","key":"2025082608265606600_bib13","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41423-019-0321-2","article-title":"LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells [published correction appears in Cell Mol Immunol. 2020;17(3):302-304]","volume":"17","author":"Li","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"8","key":"2025082608265606600_bib14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"28","key":"2025082608265606600_bib15","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.20.03048","article-title":"Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the phase III Children's Oncology Group Trial AAML0531","volume":"39","author":"Pollard","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025082608265606600_bib16","doi-asserted-by":"crossref","first-page":"116132","DOI":"10.1016\/j.biopha.2024.116132","article-title":"Immunotherapies of acute myeloid leukemia: rationale, clinical evidence and perspective","volume":"171","author":"Wu","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"2025082608265606600_bib17","doi-asserted-by":"crossref","first-page":"114260","DOI":"10.1016\/j.celrep.2024.114260","article-title":"Immunotherapeutic targeting of surfaceome heterogeneity in AML","volume":"43","author":"Bordeleau","year":"2024","journal-title":"Cell Rep"},{"issue":"2","key":"2025082608265606600_bib18","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"issue":"1","key":"2025082608265606600_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-021-01163-6","article-title":"SIRP\u03b1-\u03b1CD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells","volume":"14","author":"Tahk","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2025082608265606600_bib20","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1158\/1078-0432.CCR-25-0229","article-title":"Azacitidine, venetoclax and magrolimab in newly diagnosed and relapsed refractory acute myeloid leukemia: phase 1b\/2 study and correlative analysis","volume":"31","author":"Daver","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"36","key":"2025082608265606600_bib21","doi-asserted-by":"crossref","first-page":"13,341","DOI":"10.1073\/pnas.0405370101","article-title":"Control of dendrite arborization by an Ig family member, dendrite arborization and synapse maturation 1 (Dasm1)","volume":"101","author":"Shi","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"36","key":"2025082608265606600_bib22","doi-asserted-by":"crossref","first-page":"13,346","DOI":"10.1073\/pnas.0405371101","article-title":"The immunoglobulin family member dendrite arborization and synapse maturation 1 (Dasm1) controls excitatory synapse maturation","volume":"101","author":"Shi","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025082608265606600_bib23","doi-asserted-by":"crossref","first-page":"105476","DOI":"10.1016\/j.neubiorev.2023.105476","article-title":"The role of cell adhesion molecule IgSF9b at the inhibitory synapse and psychiatric disease","volume":"156","author":"Clarin","year":"2024","journal-title":"Neurosci Biobehav Rev"},{"key":"2025082608265606600_bib24","doi-asserted-by":"crossref","first-page":"105407","DOI":"10.1016\/j.ebiom.2024.105407","article-title":"Plasma proteomic signatures of liver steatosis and fibrosis in people living with HIV: a cross-sectional study","volume":"109","author":"van Eekeren","year":"2024","journal-title":"EBioMedicine"},{"issue":"1","key":"2025082608265606600_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41467-021-27794-4","article-title":"Genomic alterations and evolution of cell clusters in metastatic invasive micropapillary carcinoma of the breast","volume":"13","author":"Shi","year":"2022","journal-title":"Nat Commun"},{"issue":"20","key":"2025082608265606600_bib26","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1158\/0008-5472.CAN-22-3115","article-title":"Targeting the immunoglobulin IGSF9 enhances antitumor T-cell activity and sensitivity to anti-PD-1 immunotherapy","volume":"83","author":"Liu","year":"2023","journal-title":"Cancer Res"},{"key":"2025082608265606600_bib27","doi-asserted-by":"crossref","first-page":"101067","DOI":"10.1016\/j.neo.2024.101067","article-title":"IGSF9 promotes tumor invasion and metastasis through GSK-3beta\/beta-catenin mediated EMT in lung cancer","volume":"58","author":"Luan","year":"2024","journal-title":"Neoplasia"},{"issue":"6","key":"2025082608265606600_bib28","doi-asserted-by":"crossref","first-page":"101572","DOI":"10.1016\/j.xcrm.2024.101572","article-title":"CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia","volume":"5","author":"Caulier","year":"2024","journal-title":"Cell Rep Med"},{"issue":"6","key":"2025082608265606600_bib29","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"issue":"1","key":"2025082608265606600_bib30","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41467-022-29668-9","article-title":"Allogeneic TCR\u03b1\u03b2 deficient CAR T-cells targeting CD123 in acute myeloid leukemia","volume":"13","author":"Sugita","year":"2022","journal-title":"Nat Commun"},{"issue":"19","key":"2025082608265606600_bib31","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2025082608265606600_bib32","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"issue":"10","key":"2025082608265606600_bib33","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","article-title":"A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML","volume":"26","author":"John","year":"2018","journal-title":"Mol Ther"},{"issue":"11","key":"2025082608265606600_bib34","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s43018-023-00652-6","article-title":"Structural surfaceomics reveals an AML-specific conformation of integrin beta(2) as a CAR T cellular therapy target","volume":"4","author":"Mandal","year":"2023","journal-title":"Nat Cancer"},{"issue":"5","key":"2025082608265606600_bib35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1006\/geno.2002.6757","article-title":"Cloning and characterization of Igsf9 in mouse and human: a new member of the immunoglobulin superfamily expressed in the developing nervous system","volume":"79","author":"Doudney","year":"2002","journal-title":"Genomics"},{"issue":"3","key":"2025082608265606600_bib36","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s43018-023-00522-1","article-title":"Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity","volume":"4","author":"Wu","year":"2023","journal-title":"Nat Cancer"},{"issue":"6","key":"2025082608265606600_bib37","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression [published correction appears in Cell Rep. 2017;19(6):1189-1201]","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"issue":"14","key":"2025082608265606600_bib38","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2008-04-148643","article-title":"Role of leukemia cell invadosome in extramedullary infiltration","volume":"114","author":"Stefanidakis","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2025082608265606600_bib39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"2025082608265606600_bib40","doi-asserted-by":"crossref","first-page":"e2306309","DOI":"10.1002\/advs.202306309","article-title":"Rational identification of novel antibody-drug conjugate with high bystander killing effect against heterogeneous tumors","volume":"11","author":"Guo","year":"2024","journal-title":"Adv Sci"},{"issue":"12","key":"2025082608265606600_bib41","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1038\/s41588-024-01999-x","article-title":"Single-cell analysis dissects heterogeneity of leukemias with complex karyotypes","volume":"56","author":"Lepp\u00e4","year":"2024","journal-title":"Nat Genet"},{"issue":"1","key":"2025082608265606600_bib42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41408-023-00953-0","article-title":"Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure","volume":"13","author":"Mozaffari Jovein","year":"2023","journal-title":"Blood Cancer J"},{"issue":"5","key":"2025082608265606600_bib43","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","article-title":"AML treatment: conventional chemotherapy and emerging novel agents","volume":"45","author":"Forsberg","year":"2024","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"2025082608265606600_bib44","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"2025082608265606600_bib45","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Oncol"},{"issue":"8","key":"2025082608265606600_bib46","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2025082608265606600_bib47","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/leu.2016.183","article-title":"Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio","volume":"31","author":"Versluis","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2025082608265606600_bib48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s40425-019-0611-3","article-title":"Gal9\/Tim-3 expression level is higher in AML patients who fail chemotherapy","volume":"7","author":"Dama","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"12","key":"2025082608265606600_bib49","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41577-024-01062-0","article-title":"Defining myeloid-derived suppressor cells","volume":"24","author":"Akkari","year":"2024","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2025082608265606600_bib50","doi-asserted-by":"crossref","first-page":"10832","DOI":"10.1038\/s41467-024-55051-x","article-title":"Bone marrow endothelial progenitor cells remodelling facilitates normal hematopoiesis during acute myeloid leukemia complete remission","volume":"15","author":"Xing","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"2025082608265606600_bib51","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1038\/s41467-021-26282-z","article-title":"Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy","volume":"12","author":"Abbas","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"2025082608265606600_bib52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: from enhancement to normalization [published correction appears in Cell. 2019;176(3):677]","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"2025082608265606600_bib53","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/s41591-025-03698-4","article-title":"PD-L1 and the dawn of modern cancer immunotherapy","volume":"31","author":"Chen","year":"2025","journal-title":"Nat Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4217\/2407233\/blooda_adv-2025-016432-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4217\/2407233\/blooda_adv-2025-016432-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T12:27:11Z","timestamp":1756211231000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/16\/4217\/537798\/IGSF9-targeted-therapy-inhibits-the-progression-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":53,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,8,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016432","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,26]]},"published":{"date-parts":[[2025,8,15]]}}}